Thanks to everyone for making our Bio International meeting in Boston a huge success
Developing the Next Generation of Therapeutics for the Chinese Market
About Us
Who We Are
Kinalta Therapeutics, Inc. is a US based pharmaceutical company using a robust and novel approach to identify, license and develop New Chemical Entities for unmet medical needs in the Chinese market. We are a team of pharma industry experts with extensive experience in small molecule drug discovery, development and regulatory approval in the US, EU and China. With significant financial backing, we are building a robust pipeline that will address unmet needs in China and other unserved markets with the initial focus on new therapeutics for China, and then further development in Global Markets.
Our Mission
Kinalta Therapeutics is committed to bringing unique and innovative pharmaceutical assets to the China market. We are currently identifying early-stage New Chemical Entities (NCE), acquiring the rights on a global basis (or China only) and then continuing development and commercialization efforts. Kinalta’s strategy is to focus initial development activities on regulatory approval in China, and then explore clinical development in additional global markets.
Our Approach
Our teams assess opportunities based on multiple criteria including: asset development stage, target market(s), product indications, commercial aspects, and intellectual property, among others. These criteria help us to provide a framework for consistent and objective feedback to our partners, whether we decide to move forward with the opportunity or not.
Our Pipeline Development Strategy
Therapeutic Area Focus
We are primarily interested in the following therapeutic areas but will also review adjacent opportunistic areas:
Liver Disease
Non-alcoholic fatty liver disease (NAFLD); Non-alcoholic steatohepatitis (NASH); Hepatocellular carcinoma (HCC);
Hepatic steatosis; Hepatitis B virus (HBV); Alcoholic liver disease (ALD)
Pulmonary Disease
Idiopathic pulmonary fibrosis (IPF); Asthma; COPD
Pain and Inflammation
Neuropathic pain; Nociceptive pain; Osteoarthritis
Kidney Disease
Diabetic nephropathy; Acute kidney disease (AKI); Kidney fibrosis; Chronic kidney disease (CKD)
NCE Focus
Development Stage
Pre-Clinical Through End Phase 1
Molecule Type
Small Molecule; Synthetic Peptide
Routes of Administration
Oral, IV, Inhaled
Must Have
Strong IP coverage and runway to allow for development and commercialization
Out of Scope
Biologics
Generics
Medical Devices
Events
June 2018
Kanalta Therapeutics is delighted to announce their attendance at the 2018 Bio International Conference in Boston, June 4-7